SCHEMBL6078735

SCHEMBL6078735

NC(=O)C1CCCCC1NS(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.54
ALDH1A1 P00352 6/20 0.54
THRB P10828 1/20 0.54
LMNA P02545 5/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
GAA P10253 2/20 0.53
CRHBP P24387 4/20 0.53
CRHR2 Q13324 4/20 0.53
MCOLN3 Q8TDD5 1/20 0.53
MAPT P10636 1/20 0.51
HTT P42858 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
HSP90AA1 P07900 1/20 0.50
KDM4E B2RXH2 2/20 0.49
TSHR P16473 1/20 0.49
KMT2A Q03164 1/20 0.49
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
RECQL P46063 1/20 0.45
F10 P00742 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6078229 1.00 MAPK1 (0.54) MAPK1ALDH1A1THRBLMNASMN1; SMN2
SCHEMBL6077223 1.00 MAPK1 (0.54) MAPK1ALDH1A1THRBLMNASMN1; SMN2
SCHEMBL6265626 1.00 MAPK1 (0.54) MAPK1ALDH1A1THRBLMNASMN1; SMN2
SCHEMBL6078980 1.00 MAPK1 (0.54) MAPK1ALDH1A1THRBLMNASMN1; SMN2
SCHEMBL6078711 1.00 MAPK1 (0.54) MAPK1ALDH1A1THRBLMNASMN1; SMN2
SCHEMBL6078669 0.99 MAPK1 (0.53) MAPK1ALDH1A1THRBLMNASMN1; SMN2
SCHEMBL6078665 0.99 MAPK1 (0.53) MAPK1ALDH1A1THRBLMNASMN1; SMN2
SCHEMBL6078662 0.99 MAPK1 (0.53) MAPK1ALDH1A1THRBLMNASMN1; SMN2
SCHEMBL6078081 0.97 ALDH1A1 (0.51) MAPK1ALDH1A1THRBLMNASMN1; SMN2
SCHEMBL6078078 0.97 ALDH1A1 (0.51) MAPK1ALDH1A1THRBLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7084178-B2 Antiamyloid phenylsulfonamides: N-cycloalkylcarboxamides derivatives BRISTOL-MYERS SQUIBB COMPANY (US) 2006-08-01 US disclosed
WO-2005054180-A1 ANTIAMYLOID PHENYLSULFONAMIDES: N-CYCLOALKYLCARBOXAMIDES DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2005-06-16 WO disclosed
US-20050113442-A1 Antiamyloid phenylsulfonamides: N-cycloalkylcarboxamides derivatives BRISTOL-MYERS SQUIBB COMPANY 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113442-A1 Antiamyloid phenylsulfonamides: N-cycloalkylcarboxamides derivatives APP, PSEN1, PSEN2 MAPK1 2739/4885ALDH1A1 3997/4885THRB 3065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.